Table 3 Clincial Trials testing Live-attenuated MeV-derived vaccines.
From: Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines
Trial number | Virus | Disease | Phase | Institution | Status | Refs. |
---|---|---|---|---|---|---|
EudraCT 2013-001084-23 | MV-CHIK | Chikungunya fever | I | Themis Biosciences | Completed | |
NCT01320176 | MV1-F4-CT1 | AIDS | I | Institut Pasteur | Completed | Â |
NCT02861586 | MV-CHIK | Chikungunya fever | II | Themis Biosciences | Completed | |
NCT02996890 | MV-ZIKA | Zika fever | I | Themis Biosciences | Completed | Â |
NCT03028441 | MV-CHIK | Chikungunya fever | I | NIAID | Completed | Â |
NCT03101111 | MV-CHIK | Chikungunya fever | II | Themis Biosciences, Walter Reed Army Institute of Research | Completed, results posted | Â |
NCT03635086 | MV-CHIK | Chikungunya fever | II | Themis Biosciences | Completed, results posted | Â |
NCT03807843 | MV-CHIK | Chikungunya fever | II | Themis Biosciences, Walter Reed Army Institute of Research | Completed, results posted | Â |
NCT04033068 | MV-ZIKA-RSP | Zika fever | I | Themis Biosciences | Completed, results posted | Â |
NCT04055454 | MV-LASV | Lassa fever | I | Themis Biosciences | Completed | Â |
NCT04497298 | TMV-083 / V-591 | COVID-19 | I | Institut Pasteur, Themis Biosciemces, CEPI | Completed | |
NCT04498247 | V591 | COVID-19 | I / II | Merck Sharp & Dohme | Terminated |